In vitro and in vivo assays have both demonstrated the role of vegf as a mitogen and angiogenesis inducer; bevacizumab has been shown in experimental models to reduce the growth rate of tumours, with decreased vessel density in bevacizumab-treated specimens 14. The gene discussed is VEGFA; the disease is neoplasm.